GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (TSXV:AQS) » Definitions » Repurchase of Stock

Aequus Pharmaceuticals (TSXV:AQS) Repurchase of Stock : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Repurchase of Stock?

Aequus Pharmaceuticals's Repurchase of Stock for the three months ended in Sep. 2024 was C$0.00 Mil.

Aequus Pharmaceuticals's Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.


Aequus Pharmaceuticals Repurchase of Stock Historical Data

The historical data trend for Aequus Pharmaceuticals's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Repurchase of Stock Chart

Aequus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aequus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aequus Pharmaceuticals Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.
Executives
Doug Janzen Director, Senior Officer

Aequus Pharmaceuticals Headlines

No Headlines